top of page
  • Not yet recruiting

NCT05231629: Phase 2: Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (MASTER-2)

MASTER-2

NCT05231629: Phase 2: Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (MASTER-2)

master 2 trial myeloma MRD Costa

NCT05231629: Phase 2: Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (MASTER-2)


This research study will determine the proportion of patients with lowest minimal residual disease (MRD) response obtainable after receiving 6 cycles of study treatment. Minimal residual disease is multiple myeloma cells below the level of 1 cancer cell out of 100,000 in the bone marrow.


Sponsor

University of Alabama at Birmingham


Collaborator

Janssen Scientific Affairs, LLC

 

ClinicalTrials.gov Identifier: NCT05231629

Official Title: MRD-Guided Sequential Therapy For Deep Response in Newly Diagnosed Multiple Myeloma - MASTER-2 Trial

First Posted: February 9, 2022


Click here for details on ClinicalTrials.gov

 

Drug: Dara-VRd intensification, Dara-R maintenance

Drug: AHCT intensification, Dara-R maintenance

Drug: AHCT intensification, Tec-Dara consolidation, Tec-Dara maintenance

Drug: AHCT intensification, Dara-R consolidation, Dara-R maintenance

Drug: Dara-VRd induction

 

Locations

United States, Alabama

 

Related Post:

MASTER TRIAL - Dara KRd - Multiple Myeloma Clinical Trials (themyelomaclinicaltrials.com)


Posts Archive
bottom of page